365 related articles for article (PubMed ID: 18375647)
1. A predictive probability design for phase II cancer clinical trials.
Lee JJ; Liu DD
Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.
Li Y; Mick R; Heitjan DF
Clin Trials; 2012 Jun; 9(3):293-302. PubMed ID: 22523304
[TBL] [Abstract][Full Text] [Related]
4. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
5. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
6. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
7. A confidence function-based posterior probability design for phase II cancer trials.
Shan M
Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
[TBL] [Abstract][Full Text] [Related]
8. Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.
Berry SM; Broglio KR; Groshen S; Berry DA
Clin Trials; 2013 Oct; 10(5):720-34. PubMed ID: 23983156
[TBL] [Abstract][Full Text] [Related]
9. Adaptive designs in critical care trials: a simulation study.
Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
[TBL] [Abstract][Full Text] [Related]
10. Stopping rules for phase II studies.
Stallard N; Whitehead J; Todd S; Whitehead A
Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
[TBL] [Abstract][Full Text] [Related]
11. Bayesian interim analysis of phase II cancer clinical trials.
Heitjan DF
Stat Med; 1997 Aug; 16(16):1791-802. PubMed ID: 9280033
[TBL] [Abstract][Full Text] [Related]
12. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
Ryan EG; Brock K; Gates S; Slade D
BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
[TBL] [Abstract][Full Text] [Related]
13. Bayesian monitoring of phase II trials in cancer chemoprevention.
Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
[TBL] [Abstract][Full Text] [Related]
14. A predictive probability interim design for phase II clinical trials with continuous endpoints.
Liu M; Dressler EV
Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
[TBL] [Abstract][Full Text] [Related]
15. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
16. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
17. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
18. Comparing Bayesian early stopping boundaries for phase II clinical trials.
Jiang L; Yan F; Thall PF; Huang X
Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
[TBL] [Abstract][Full Text] [Related]
19. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
20. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
Wason JM; Trippa L
Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
